Cargando…
CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA
Brain metastases (BrM) commonly occur in renal cell carcinoma (RCC) and often present with hemorrhagic features. The distribution patterns of BrM in RCC and their associations with clinical outcomes remain unclear. We conducted a retrospective neuroanatomical distribution analysis combined with clin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402364/ http://dx.doi.org/10.1093/noajnl/vdad070.031 |
_version_ | 1785084859471888384 |
---|---|
author | Kamson, David Olayinka Feinaj, Ardit Markowski, Mark Yerrapragada, Anirudh Elias, Roy Shenderov, Eugene Bettegowda, Chetan Singla, Nirmish Ged, Yasser |
author_facet | Kamson, David Olayinka Feinaj, Ardit Markowski, Mark Yerrapragada, Anirudh Elias, Roy Shenderov, Eugene Bettegowda, Chetan Singla, Nirmish Ged, Yasser |
author_sort | Kamson, David Olayinka |
collection | PubMed |
description | Brain metastases (BrM) commonly occur in renal cell carcinoma (RCC) and often present with hemorrhagic features. The distribution patterns of BrM in RCC and their associations with clinical outcomes remain unclear. We conducted a retrospective neuroanatomical distribution analysis combined with clinical review of our surgical RCC BrM cohort. Sixty-seven BrMs from 46patients (age 63±10years, 25males) were included. The majority of BrM (55%) were found in the left hemisphere, with frontal (45%), parietal (21%), and occipital (18%) lobes being the most commonly affected areas. Hemosiderin deposits, as detected by MRI, were present in 82% of BrM, while hemorrhage, as detected by CT, was present in 80% of BrM. Patients with solitary BrM had a higher KPS (p=0.006) and lower disease burden (p=0.004) compared to those with multiple BrM. Mean 1D and 2D(RANO) tumor dimensions were 2.0±1.1cm and 4.7±4.9cm2, respectively, and correlated with the neutrophil count at BrM diagnosis (r=0.3; p=0.01). Hemosiderin deposits were associated with larger tumors (2.6±1.0cm vs. 1.8±0.7cm, p=0.04), lower platelet counts (p=0.01), and higher hemoglobin levels (p=0.08). Shorter Brain Metastasis-Free Survival was associated with hemosiderin deposits on MRI (log-rank p=0.04) and renal vein thrombosis (RVT) in the primary specimen (log-rank p=0.002). RVT at primary diagnosis was associated with both hemosiderin deposits on MRI (p=0.05) and hemorrhage on CT (p=0.03), and CNS progression-free survival was shorter in patients with RVT (7.3±1.7 months vs. 21.0±4.7 months). When including only significant predictors, right hemispheric BrM lateralization (HR 2.6, p=0.06), hemosiderin deposits in BrM (HR 6.5, p=0.02), and IMDC risk groups (intermediate HR=2.9; poor-risk HR=25.6; p<0.04) were independent prognostic factors for shorter OS on multivariable analysis. Our results demonstrate that mapping the BrM distribution o in RCC can provide clinically relevant insights. Hemosiderin deposits in BrM may have prognostic implications. Further analyses are ongoing. |
format | Online Article Text |
id | pubmed-10402364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104023642023-08-05 CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA Kamson, David Olayinka Feinaj, Ardit Markowski, Mark Yerrapragada, Anirudh Elias, Roy Shenderov, Eugene Bettegowda, Chetan Singla, Nirmish Ged, Yasser Neurooncol Adv Final Category: Clinical Research Methods Brain metastases (BrM) commonly occur in renal cell carcinoma (RCC) and often present with hemorrhagic features. The distribution patterns of BrM in RCC and their associations with clinical outcomes remain unclear. We conducted a retrospective neuroanatomical distribution analysis combined with clinical review of our surgical RCC BrM cohort. Sixty-seven BrMs from 46patients (age 63±10years, 25males) were included. The majority of BrM (55%) were found in the left hemisphere, with frontal (45%), parietal (21%), and occipital (18%) lobes being the most commonly affected areas. Hemosiderin deposits, as detected by MRI, were present in 82% of BrM, while hemorrhage, as detected by CT, was present in 80% of BrM. Patients with solitary BrM had a higher KPS (p=0.006) and lower disease burden (p=0.004) compared to those with multiple BrM. Mean 1D and 2D(RANO) tumor dimensions were 2.0±1.1cm and 4.7±4.9cm2, respectively, and correlated with the neutrophil count at BrM diagnosis (r=0.3; p=0.01). Hemosiderin deposits were associated with larger tumors (2.6±1.0cm vs. 1.8±0.7cm, p=0.04), lower platelet counts (p=0.01), and higher hemoglobin levels (p=0.08). Shorter Brain Metastasis-Free Survival was associated with hemosiderin deposits on MRI (log-rank p=0.04) and renal vein thrombosis (RVT) in the primary specimen (log-rank p=0.002). RVT at primary diagnosis was associated with both hemosiderin deposits on MRI (p=0.05) and hemorrhage on CT (p=0.03), and CNS progression-free survival was shorter in patients with RVT (7.3±1.7 months vs. 21.0±4.7 months). When including only significant predictors, right hemispheric BrM lateralization (HR 2.6, p=0.06), hemosiderin deposits in BrM (HR 6.5, p=0.02), and IMDC risk groups (intermediate HR=2.9; poor-risk HR=25.6; p<0.04) were independent prognostic factors for shorter OS on multivariable analysis. Our results demonstrate that mapping the BrM distribution o in RCC can provide clinically relevant insights. Hemosiderin deposits in BrM may have prognostic implications. Further analyses are ongoing. Oxford University Press 2023-08-04 /pmc/articles/PMC10402364/ http://dx.doi.org/10.1093/noajnl/vdad070.031 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: Clinical Research Methods Kamson, David Olayinka Feinaj, Ardit Markowski, Mark Yerrapragada, Anirudh Elias, Roy Shenderov, Eugene Bettegowda, Chetan Singla, Nirmish Ged, Yasser CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title | CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title_full | CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title_fullStr | CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title_full_unstemmed | CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title_short | CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA |
title_sort | clrm-09 mapping the distribution and clinical associations of brain metastases in renal cell carcinoma |
topic | Final Category: Clinical Research Methods |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402364/ http://dx.doi.org/10.1093/noajnl/vdad070.031 |
work_keys_str_mv | AT kamsondavidolayinka clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT feinajardit clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT markowskimark clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT yerrapragadaanirudh clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT eliasroy clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT shenderoveugene clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT bettegowdachetan clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT singlanirmish clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma AT gedyasser clrm09mappingthedistributionandclinicalassociationsofbrainmetastasesinrenalcellcarcinoma |